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Abstract
Serrated lesions of the colorectum are the precursors of perhaps one-third of colorectal cancers.
Cancers arising in serrated lesions are usually in the proximal colon, and account for a
disproportionate fraction of cancer identified after colonoscopy.
We sought to provide guidance for the clinical management of serrated colorectal lesions based on
current evidence and expert opinion regarding definitions, classification and significance of
serrated lesions. A consensus conference was held over 2 days reviewing the topic of serrated
lesions from the perspectives of histology, molecular biology, epidemiology, clinical aspects, and
serrated polyposis.
Serrated lesions should be classified pathologically according to World Health Organization
criteria as hyperplastic polyps, sessile serrated adenoma/polyp (SSA/P) with or without
cytological dysplasia, or traditional serrated adenoma (TSA). SSA/P and TSA are premaligant
lesions, but SSA/P is the principle serrated precursor of colorectal cancers.
Serrated lesions have a distinct endoscopic appearance, and several lines of evidence suggest that
on average they are more difficult to detect than conventional adenomatous polyps. Effective
colonoscopy requires an endoscopist trained in the endoscopic appearance of serrated lesions. We
recommend that all serrated lesions proximal to the sigmoid colon and all serrated lesions in the
rectosigmoid > 5 mm in size, be completely removed. Recommendations are made for post-
polypectomy surveillance of serrated lesions and for surveillance of serrated polyposis patients
and their relatives.
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Introduction
Serrated lesions of the colorectum are characterized histologically by a serrated (or
sawtoothed) appearance of the crypt epithelium (Figure 1a–c). Thirty years ago serrated
lesions were called “hyperplastic” polyps and were thought to have no malignant potential
(1). Since then a subset of serrated lesions has been established as the precursors of a group
of colorectal cancers (CRCs) that exhibit hypermethylation and arise primarily in the
proximal colon, and which may account for one-third of all CRCs (2–11). Subtypes of
serrated lesions (Table 1) have different molecular profiles and variable potential to develop
into CRC (12–19).
The purposes of this consensus report are to summarize the pathologic, molecular, and
endoscopic features of serrated lesions, to increase awareness of the threat posed by these
lesions, to describe the endoscopic appearance of these lesions, to stress the importance of
accurate detection and complete excision, and to provide recommendations regarding post-
resection management. Table 2 summarizes the key concepts and recommendations in this
article.
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This statement is the result of a two day consensus meeting held in Cleveland in 2010 and
sponsored by the National Institutes of Health. The panel members were chosen for their
expertise in endoscopy, surgery, pathology, epidemiology, and/or molecular aspects of
serrated lesions and/or serrated polyposis. In preparation of this report a literature review
was conducted in MEDLINE, 1996 to October, 2011, using the terms hyperplastic polyp,
serrated polyp, serrated adenoma, serrated cancer, hyperplastic polyposis syndrome, serrated
polyposis syndrome, microsatellite instability, CpG Island Methylator phenotype, and
hypermethylation.
The recommendations presented here generally and necessarily reflect expert consensus
opinion, as the levels of evidence available to support recommendations are of low or very
low quality (20). The review and recommendations reported here were not commissioned,
reviewed, or endorsed by the American College of Gastroenterology.
Pathology of serrated lesions
Overview
Serrated lesions of the colorectum are currently classified by the WHO into three general
categories (19) (Table 1). The rationale for the terminology in Table 1 has been described
previously (11, 21). The terms “sessile serrated adenoma” and “sessile serrated polyp” are
considered synonyms, and both are acceptable.
In general, the subtypes of serrated lesions are identified by cytological and architectural
features and by the location and extent of the proliferative zone (14, 21) as described below.
The specific causes of the cytological, architectural, and proliferative alterations are not
known, but they are presumed to result from epigenetic alterations in genes responsible for
cell proliferation and differentiation (caused by hypermethylation of promoter DNA), as
well as genetic changes such as mutations in BRAF.
Hyperplastic polyps
HPs are characterized by the presence of straight crypts which extend symmetrically from
the surface of the polyp to the muscularis mucosae without significant distortion (Figure 1a–
c). The crypts are typically wider at the polyp surface compared to the base, and do not show
horizontal or irregular branching (Figure 1a–c). Similarly, the degree of “serration” is more
pronounced in the upper half and surface of the polyps than at the base. Depending on the
subtype (see below), the epithelium may be lined with a variety of cell types including
microvesicular mucinous cells, goblet cells and undifferentiated cells. Neuroendocrine cells
are often prominent at the base of the polyp. In general, mitoses are confined to the basal
half of the polyp. In many cases, the basement membrane underneath the surface epithelium
is thickened as well. Only minimal cytological atypia is present in HPs. The cells show
small oval or slightly elongated nuclei, without stratification or hyperchromaticity. It is
important to consider overall architecture, since cytological atypia without significant
architectural changes may be due to regenerative changes in an inflamed hyperplastic polyp.
HPs can be subdivided histologically into microvesicular (MVHP), goblet cell (GCHP), and
mucin poor (MPHP) types based on the characteristics of lining epithelium. MPHPs are rare,
and little is known about their molecular features or natural history. MVHPs and GCHPs are
well characterized and display considerable differences in molecular and histologic features
as well as anatomic distribution within the colon. Although we describe the pathologic
features of these HP subtypes, any clinical importance of the distinctions is currently
uncertain.
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MVHPs are characterized by the presence of small droplet (“microvesicular”) mucin within
the cytoplasm of most cells. Scattered goblet cells are common as well (Figure 1a). MVHPs
are located predominantly in the left colon, although 10–15% occur in the transverse and
right colon. Multiple MVHPs are common, particularly in the rectum.
In contrast to MVHPs, GCHPs are characterized by the nearly exclusive presence of goblet
cells (Figure 1b). Cells with microvesicular mucin are not present. Compared to MVHPs,
GCHPs show few or no luminal serrations. Although the proliferative zone remains located
in the basal portion of the crypts, it is often limited to only a few cells. GCHPs are also more
common in the left colon (≈90%), and are typically very small (< 0.5 cm).
MPHPs show little or no cytoplasmic mucin. They have a luminal serration pattern similar
to MVHPs, but also reveal increased nuclear atypia in the form of large, round,
hyperchromatic nuclei, but without pseudostratification (Figure 1c). One theory is that
MPHPs represent injured MVHPs with inflammation and reactive epithelial changes.
Sessile serrated adenoma/polyp
SSA/Ps are characterized by the presence of a disorganized and distorted crypt growth
pattern which is usually easily identifiable upon low power microscopic examination (14,
21) (Figure 2a). Crypts, particularly at the basal portion of the polyp, may appear dilated
and/or branched, particularly in the horizontal plane, which leads to the formation of “boot,”
“L,” or “anchor”-shaped crypts (Figure 2a). The basal half of the crypts often contain
excessive (“hyper”) serration and mature goblet cells and mucinous cells. Upon Ki67
staining (a stain for proliferating cells), positive cells may be located anywhere in the crypt
from the base to the surface, and often in an irregular and asymmetric pattern (21). Other
common cytological features include various degrees of nuclear atypia (e.g., cells with open
nuclei and prominent small nucleoli), dystrophic goblet cells, and an absence of
neuroendocrine cells. Foci of cells with elongated penicillate nuclei and eosinophilic
cytoplasm that are reminiscent of cells seen in TSAs (see below) may be present. SSA/Ps
often produce excessive extracellular mucin, and it is not unusual to see mucin fill the lumen
of dilated crypts and coat the surface of the polyp. Some SSA/Ps show prominent lipoma-
like adipose tissue in the submucosa, but it is unclear if this phenomenon represents a
chance association of SSA/P with a submucosal lipoma or some form of epithelial-
mesenchymal interaction. Herniation of crypts through the muscularis mucosae, giving rise
to a “pseudoinvasive” or “inverted” growth pattern, is not unusual, but the pathogenesis of
this finding is unknown. Pseudoinvasion can also be seen in hyperplastic polyps and
therefore, while more common in SSA/Ps, is not pathognomonic of SSA/P.
Differential Diagnosis: Microvesicular Hyperplastic Polyp (MVHP) vs Sessile Serrated
Adenoma (SSA/P)
Serrated lesions may show MVHP pathology in one area and SSA/P morphology, such as
dilated and irregular crypts, in another. These lesions have been sometimes interpreted as
evidence of progression of MVHP to SSA/P, but MVHP-like features could simply be part
of the histologic spectrum of SSA/P. A difficult and unresolved diagnostic problem relates
to polyps that show nearly exclusive MVHP morphology, but in addition show only a few
(or even just one), irregular, hyperdilated and distorted crypts of the type seen in SSA/P.
Unfortunately, the minimum criteria necessary to establish a diagnosis of an SSA/P have not
been set. We recommend that the presence of at least one unequivocal architecturally
distorted, dilated, and/or horizontally branched crypt, particularly if it is associated with
inverted maturation, is sufficient for a diagnosis of SSA/P. In clinical practice there is
substantial interobsever variation among pathologists in the differentiation of SSA/P from
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HP, and agreement between pathologists is moderate at best, including between expert
pathologists (22–24).
Sessile serrated adenoma/polyp (SSA/P) with cytological dysplasia
Recent data suggest that SSA/P with foci of conventional (tubular or tubulovillous)
adenoma-like dysplasia represent progression towards carcinoma. Preliminary evidence
indicates that a substantial portion of these lesions demonstrate inactivation of the mismatch
repair gene MLH1, and the dysplastic areas often demonstrate microsatellite instability (25).
Such lesions were previously reported in the literature as “mixed hyperplastic/adenomatous
polyps”. The term “mixed polyp” is discouraged because it doesn’t convey the concept that
combined features represent progression of an SSA/P towards carcinoma, and that the
cytologically dysplastic portion has different molecular characteristics from conventional
adenomas.
Histologically, SSA/Ps with conventional adenoma-like dysplasia usually show a portion of
the polyp with typical SSA/P morphology and another with an abrupt transition to
cytologically dysplastic areas (Figure 2b). Conventional adenoma-like dysplastic areas are
characterized by the presence of elongated cells with penicillate and hyperchromatic
pseudostratified nuclei, amphophilic cytoplasm, and increased mitoses. The dysplastic areas
look similar to a conventional tubular or tubulovillous adenoma cytologically. Although
areas of conventional adenomatous dysplasia may show a range of cytological atypia with
features similar to “low-grade” or “high-grade” dysplasia in a conventional adenoma, the
significance of the grade of dysplasia in SSA/P has not been evaluated. We recommend that
SSA/P with any conventional cytological dysplasia be considered an “advanced” polyp with
clinical significance similar to high-grade dysplasia in conventional adenomas.
Although poorly studied, another form of “dysplasia” may rarely be seen in SSA/P, which is
referred to here as “serrated dysplasia” (19). Some cases may show a proliferation of
atypical cells that are more cuboidal in shape, have eosinophilic cytoplasm, enlarged round
nuclei with open vesicular prominent chromatin, and prominent nucleoli in addition to
increased mitoses. Although not particularly serrated in its architectural growth pattern due
to the presence of prominent eosinophilic cytoplasm, some experts believe that serrated
dysplasia is also a histologic biomarker of neoplasia progression (19).
Traditional serrated adenoma
Histologically, TSAs often show a complex and distorted tubulovillous or villous
(“filiform”) configuration (Figure 3). In many cases, the villi are elongated with bulbous
tips, and have been termed filiform TSAs (26). A recent study described a characteristic
pattern of budding of proliferative crypts situated perpendicular to the long axis of filiform
or villous structures of TSAs (ectopic crypt formation) (21). The authors suggested that this
phenomenon is related to loss of (normal) anchorage of crypts to the underlying muscularis
mucosae. It is the most characteristic histologic feature of this type of polyp. The
predominant cell in TSA has abundant eosinophilic cytoplasm and a basal or centrally
placed slightly elongated nucleus with an open/even chromatin pattern. The epithelium is
usually pseudostratified but shows little if any proliferative activity and is often interpreted
as a form of dysplasia. There is some controversy as to whether this epithelium represents a
type of “metaplasia” or “senescence” rather than true dysplasia since it differs from the more
cytologically atypical and proliferative appearance of dysplastic epithelium in conventional
adenomas. Although a prominent and characteristic feature of TSAs, this type of
eosinophilic epithelium may also be present in SSA/P with or without conventional
adenoma-like cytological dysplasia. Goblet cells may also be a component of serrated crypts
in TSA, and in some cases are prominent.
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Both conventional adenoma-like dysplasia and serrated dysplasia can be observed in TSA.
With neoplastic progression, it is believed that TSAs acquire increasing degrees of
cytological atypia prior to the development of carcinoma. However, there is no consensus on
identification and grading of dysplasia in TSA. Until agreement is reached, conventional
adenoma-like dysplasia should be graded similarly to the way it is graded in conventional
adenomas (high-grade vs. low-grade). A recent study showed that 25% of TSAs from Korea
had changes described as high grade dysplasia and 8% showed intramucosal
adenocarcinoma (27). High-grade serrated dysplasia shows cells with strongly eosinophilic
cytoplasm, but in contrast to the eosinophilic epithelium characteristic of many TSAs, these
eosinophilic cells show increased size of the nuclei, hyperchromaticity, stratification, and
increased mitotic activity. The luminal serrated growth pattern is often more exaggerated,
complex, and distorted than typical TSAs. Some cases may show a mixture of both types of
dysplasia (both serrated and conventional adenoma-like) within the same polyp or even
within the same crypt/villous unit. The risk of malignancy in TSA, and the rapidity of
progression to carcinoma, is unknown.
As discussed in the molecular section of this article, there is a greater heterogeneity in the
molecular profile of TSA compared to SSA/P. This may be partly due to inconsistency in
the diagnostic criteria used for this lesion.
Unclassifiable serrated polyps
Some “serrated” lesions may be difficult to classify into one of the above discrete categories.
Aside from histologic difficulties due to overlapping features, logistical factors such as poor
orientation of specimens, poor staining, severe cautery artifact, or insufficient tissue may
impede the ability to establish a precise diagnosis. In such cases, the term “serrated polyp
unclassified” is acceptable. However, pathologists should make their best attempt to
determine whether dysplasia is present, even when the diagnosis is difficult.
Conventional tubular, tubulovillous, or villous adenomas may occasionally show areas with
a serrated growth pattern. Unfortunately, the biological significance of these polyps has not
been studied. They are generally distinguished from other types of serrated polyps by the
absence of areas of SSA/P or TSA morphology. The term “conventional adenoma (tubular,
tubulovillous, villous) with a serrated growth pattern” is an acceptable term for these lesions.
A recent study identified a distinctive group of conventional adenomas that met the above
criteria and additionally exhibited cystic glands and bright cytoplasmic eosinophilia (28).
The authors reported these lesions to be KRAS and BRAF wild type and CIMP-low. In that
study, polyps were found in patients with at least one synchronous SSA/P.
Molecular features of the serrated pathway of carcinogenesis
Every colorectal cancer has a unique molecular profile (29). However, there are at least
three general molecular mechanisms by which genetic and epigenetic events can lead to
CRC: chromosomal instability (CIN), defective DNA mismatch repair leading to
microsatellite instability (MSI), and epigenetic DNA promoter hypermethylation leading to
the CpG island methylator phenotype (CIMP). Although there can be overlap of these
mechanisms within any single cancer, the dominant mechanism has distinct clinical
associations including the type of benign precursor lesion. The epigenetic CIMP pathway is
considered to be the major mechanism driving the serrated pathway to CRC.
Serrated polyp-carcinoma sequence: the epigenetic (hypermethylator) mechanism
This mechanism of colorectal carcinogenesis is based on abnormal promoter CpG island
hypermethylation (29–36). Methylation of CpG islands within promoter regions of genes is
a normal way of reducing gene expression. More methylation means less expression, and if
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the gene being silenced is a tumor suppressor gene, then loss of function may facilitate
carcinogenesis. The extent of promoter CpG island hypermethylation in neoplasms varies
considerably. Hypermethylation of some genes occurs in most CRCs, but it is the global
nature of the methylation that distinguishes the subset of tumors labeled “CIMP-high.”
CIMP-high can be detected in tumors by screening a panel of genes for the degree of
methylation (30).
Silencing a gene through promoter hypermethylation is an “epigenetic” rather than a genetic
event since it does not involve an alteration in DNA sequence. Clinical associations with
CIMP-high CRCs include older age, female sex, and proximal tumor location (31).
Some CIMP-high CRCs resemble Lynch-associated CRCs in that they have loss of DNA
mismatch repair capability, evidenced by the presence of MSI. In these tumors, mismatch
repair function is lost by promoter hypermethylation of MLH1 (one of several genes
required for DNA mismatch repair) rather than by a germline mutation as occurs in Lynch
syndrome. These sporadic MSI CRCs also have CIMP, and account for about 15% of all
colon cancers and 4% of rectal cancers (29, 31). BRAF mutations are strongly associated
with CIMP-high CRCs where they act as an alternative to the KRAS mutations that occur
commonly in CIN cancers (35–38).
Recognition of these three broad molecular mechanisms underlying CRC (CIN, MSI, and
CIMP) provides molecular tools with which to identify their respective precursor lesions
(Table 3). Many studies have shown common molecular features between benign serrated
lesions and CIMP-high CRCs (39–44). Some HPs and most SSA/Ps have BRAF mutations
and are CIMP-high, and SSA/Ps with cytological dysplasia frequently have MLH1
hypermethylation and MSI in their dysplastic foci. Although some conventional adenomas
are CIMP-high (45, 46), it is less common than in SSA/Ps and conventional adenomas do
not have BRAF mutations or MSI.
The association of molecular markers with the histologic subtypes of benign serrated lesions
and CIMP-high tumors has led to the proposal of an HP → SSA/P → SSA/P with
cytological dysplasia → cancer sequence (Figure 4). This sequence occurs most commonly
in the proximal colon, though recent evidence indicates a progressive increase in CIMP-
high, MSI-high, and BRAF mutations in each colon segment from rectum through ascending
colon, suggesting that risk for CIMP-high tumors increases proximally in a continuous
rather than dichotomous (colon divided at the splenic flexure) fashion (47).
TSAs are much less common than SSA/Ps, so there are fewer data on their molecular profile
(16, 48). TSAs appear to be more molecularly diverse than SSA/Ps in that they may have
either KRAS or BRAF mutations or neither, and either low or high levels of CIMP. TSAs
typically do not show hypermethylation of MLH1 or develop MSI, but they do commonly
have hypermethylation of the DNA repair gene MGMT (O6-methylguanine-DNA
methyltransferase) (49). MGMT promoter methylation has been associated with both CIMP-
low and -high CRCs (50). Since some HPs do share molecular features of TSAs (KRAS
mutations and CIMP) (Table 3), it has been suggested that the TSA pathway could diverge
from the SSA pathway on the basis of KRAS vs BRAF mutations and/or MLH1 vs MGMT
hypermethylation within subsets of HPs. However, a definite precursor of TSA has not been
established.
Epidemiology of serrated lesions
Knowledge of the epidemiology of serrated lesions is primarily derived from studies of
“hyperplastic” polyps prior to the recognition of the three subtypes described above.
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Autopsy studies demonstrate variable prevalence rates of serrated lesions but collectively
indicate that 25–50% of white adults have one or more serrated lesions (51–58).
Colonoscopic studies show similarly variable but lower prevalence rates (59–64). The
overall prevalence of serrated lesions increases only slightly with age during adulthood (51–
61) in contrast to conventional adenomas which increase sharply with age (51, 54, 58).
Hyperplastic polyps are more common in men in some (51, 52, 54, 57, 58, 61, 65) but not all
studies (59, 66, 67). Overall, serrated lesions are most common in the sigmoid colon and
rectum (51–55, 66, 67), but the distribution varies by histological subtype. HPs account for
70–95% of all serrated lesions and are predominantly left-sided (66–70). SSA/Ps comprise
5–25% of serrated lesions and are predominately right sided (66–74). TSAs are much less
common than SSA/Ps. In clinical studies the prevalence of SSA/Ps is generally less than 2%
(72, 73).
Risk factors for serrated lesions
Distal serrated lesions are associated with cigarette smoking (61–63, 65, 75–77). Alcohol
intake (59, 61, 75, 78, 79), fiber intake (75, 79), calcium intake (60, 78, 79), NSAID use (60,
75, 79), family history of colorectal cancer (59, 60, 65, 78, 79), and high body mass index
(54, 55, 59, 75, 79) have had inconsistent associations with distal serrated lesions (60, 61,
75, 78, 79). Physical activity has been inversely associated with risk (79), at least in men
(75), and folate intake has also been inversely associated with the risk of distal serrated
lesions (78). There are scant epidemiological data regarding right-sided serrated polyps, but
cigarette smoking has been associated with proximal (77, 80, 81) as well as distal (82)
serrated lesions, and with an overall higher risk of SSA/Ps and large SSA/Ps (83).
Association between serrated lesions and adenomas
Autopsy studies show a correlation between numbers of adenomas and serrated lesions,
although with different anatomic distributions for the two types of lesions (51, 54–56, 58).
One endoscopic series reported no association between the presence of adenomas and
serrated lesions (84). At most there is a modest association between distal serrated lesions
and proximal adenomas (85). Individuals with SSA/P tend to harbor synchronous adenomas
(67–70, 73), HPs (73), and other SSA/Ps (69). Both large and/or proximal serrated lesions
have been associated with an increased risk of synchronous advanced conventional
neoplasia (81), and advanced neoplasia has been associated with the presence of large
serrated lesions (86, 87). Individuals with both SSA/Ps and conventional adenomas are
older, harbor more numerous, larger, and more dysplastic SSA/Ps and conventional
adenomas compared to individuals with only SSA/Ps or conventional adenomas (88). Any
association between HPs and adenomas in Lynch syndrome has been inconsistent (89–92).
No consistent association has emerged between serrated lesions found on colonoscopy and
subsequent adenoma risk in asymptomatic individuals (81, 93–98). Some studies have
shown serrated lesions to be associated with a higher risk of metachronous serrated lesions,
just as adenomas are associated with a higher risk of metachronous adenomas (93, 99, 100),
though patients with serrated lesions and/or adenomas can demonstrate either type of lesion
upon follow up.
Association between serrated lesions and cancer
Case reports describe development of colorectal cancer in serrated lesions left in situ (101,
102). There are numerous reported cases of carcinoma with residual SSA/P (103, 104). In a
pathology series of 2416 SSA/Ps, 14% demonstrated cytological dysplasia and 1% showed
cancer (72). The mean age was 61 years in patients with SSA/P without cytological
dysplasia, 66 years in those with SSA/P with low-grade cytological dysplasia, 72 years in
those with high-grade cytological dysplasia, and 76 years in those with SSA/P with cancer.
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These findings suggested a mean interval of 15 years for progression of SSA/P without
cytological dysplasia to cancer (72).
One autopsy study noted a stronger association between serrated lesions and colorectal
cancer than between adenomas and cancer (105), which was also found in one endoscopic
study (92).
SSA/P has been associated with synchronous colorectal cancers with MSI (106). Serrated
lesions ≥ 1 cm in size, which were likely SSA/P in most cases, were strongly associated with
synchronous cancer, particularly in the proximal colon (107). MSI-high cancers were more
likely to be accompanied by serrated lesions than microsatellite stable cancers (108). Further
studies are required to determine whether this association applies to both HP and SSA/P or
predominantly to SSA/P. In addition, synchronous colorectal cancers have higher rates of
CIMP-high, MSI, and BRAF mutation than occurs in solitary CRCs (109), suggesting that
multiplicity is associated with the serrated pathway.
SSA/P has also been associated with an increased risk of metachronous cancer. In case
series, a diagnosis of SSA/P carries more risk for subsequent cancer than a diagnosis of HP.
In one study, when 55 patients with SSA/P were followed, five (12.5%) developed cancer
during 7.2 years of follow-up compared to just one among matched controls with HP and
tubular adenoma (68). Proximal colon cancers with MSI were associated with serrated
lesions at previous colonoscopies, and increasing size of these polyps was associated with
shorter intervals between polyp and cancer diagnosis (42).
Detection of serrated lesions
The most common serrated lesion is a diminutive left-sided, pale, sessile HP (110). Some
have a translucent quality and may disappear upon air insufflation (111). Larger serrated
lesions (SSA/P) are typically similar in color to the surrounding mucosa. SSA/Ps and HPs in
the proximal colon are often covered by a tenacious mucus cap (Figure 5a). The mucus can
cause the polyps to appear yellow, green or rust-colored and appear red on narrow band
imaging (Figure 5a). Care should be taken when washing mucus off the polyp, since the
underlying lesion can be difficult to detect without it (Figure 6a–h). A recent prospective
endoscopic assessment of 158 SSA/Ps identified the mucus cap in 64% of lesions, a rim of
debris or bubbles in 52%, alteration of the contour of a fold in 37% and interruption of the
underlying mucosal vascular pattern in 32% (112).
A number of imaging techniques not usually in use in clinical practice in western countries
allow reliable differentiation of conventional adenomas from serrated lesions in real time
during colonoscopy (113). Reliable real time differentiation of HPs from SSA/Ps might not
be achievable by endoscopic techniques that image the lesion surface since the characteristic
histologic features of SSA/P are primarily in the crypt base. However, a recent study found
that a modified Kudo pit designated Type II-O is specific but not sensitive for SSA/P and
highly associated with BRAF mutation and CIMP (114). If verified, recognition of these
structures would require magnification colonoscopy, which is rarely available in western
countries.
SSA/Ps and HPs are almost always sessile or flat. TSAs tend to be bulkier than SSA/Ps and
are occasionally pedunculated, but otherwise pedunculated serrated lesions are rare. SSA/Ps
are less discrete than adenomas with borders that can be difficult to define. Large SSA/P
may develop folds and “wrinkle” when snared, a feature that gives them the appearance of
redundant mucosa. It is likely that factors that affect colonoscopy quality and detection of
flat and depressed colon neoplasms, such as bowel preparation (115–117), withdrawal time,
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thoroughness of examination, polypectomy technique, and perceptual and personality
attributes, will apply to SSA/Ps as well (118).
Detection rates of “serrated” lesions vary dramatically between endoscopists, indicating that
these lesions are significantly under-diagnosed in clinical practice (73, 119). In one study
(73), the endoscopy and pathology reports from all average risk-screening colonoscopies at
an urban academic medical center over a 3-year period were reviewed. Detection of
conventional adenomas varied significantly among endoscopists (from 13.5 to 38.4% (p <
0.001)). Detection of HPs (7.7 to 31%, p < 0.001) and SSA/Ps (0 to 2.2%, p = 0.02) also
varied significantly. Similar trends were observed for the subset of conventional adenomas,
HPs, and SSA/Ps that were located in the proximal colon. In another study (119) that
focused on the prevalence and detection rates of serrated polyps of all subtypes located
proximal to the splenic flexure, the proportion of colonoscopies with at least one proximal
serrated polyp ranged from 1% to 18%, and the detection rates per colonoscopy ranged from
0.01 to 0.26. There was a strong correlation between adenoma detection rates and proximal
serrated lesion detection rates. Logistic regression showed that the endoscopist was a more
powerful predictor than patient age or gender for proximal serrated lesion detection. These
two studies suggest that the true prevalence of serrated lesions is likely to be higher than
previously reported and show that serrated lesion detection is highly variable and operator-
dependent. Miss rates for serrated lesions have not been specifically measured in tandem
colonoscopy studies (120), but the range of detection rates described thus far indicates that
substantial numbers of endoscopists miss more than half of the serrated lesions in the
proximal colon (73, 119). Recent guidelines on the technical performance of colonoscopy
have recommended thresholds for adenoma detection by individual endoscopists, but have
not made separate recommendations for detection rates of serrated lesions (121, 122).
However, three studies suggest a strong correlation between detection of adenomas and
serrated lesions by individual endoscopists (73, 119, 123).
Adjunctive imaging methods such as chromoendoscopy, electronic chromoendoscopy
(narrow band imaging, etc.), and autofluorescence have generally not been investigated for
their value in specifically improving the detection of serrated lesions.
Table 4 summarizes the major endoscopic and clinical features of serrated lesions.
Recommendations regarding removal of serrated lesions
We recommend complete removal of all serrated lesions, except for diminutive sigmoid or
rectal lesions. Multiple diminutive (≤ 5 mm) serrated-appearing lesions in the rectum and/or
sigmoid should be randomly sampled for histology, but complete resection of all diminutive
rectosigmoid serrated lesions is unnecessary. Almost all serrated lesions can be excised
endoscopically, and the principles of resection are similar to those governing removal of
adenomas.
Three issues that can make endoscopic resection of serrated lesions difficult are shared with
adenomas: size, shape and location. Large, flat lesions are challenging to remove regardless
of histology. Lesions surrounding the appendiceal orifice or in the ileocecal valve orifice
may not be endoscopically removable. At least one issue making complete polypectomy
difficult is relatively specific to serrated lesions: identifying the border of the lesion.
Although the surface structure of serrated lesions is different from normal mucosa the true
edges of serrated lesions can be difficult to identify. Complete endoscopic resection is
important and use of a high definition colonoscope, an electronic highlighting technique
(e.g., narrow band imaging), surface dye-spraying, and/or submucosal injection of fluid
containing a contrast agent (e.g., methylene blue or indocyanine green) can assist in
identifying the lesion perimeter.
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Serrated lesions smaller than 1 cm can be resected with or without electrocautery. For all but
the tiniest lesions, cold snaring is more efficient and effective than piecemeal resection using
cold forceps (124). Cold snaring should include a narrow margin of normal mucosa around
the perimeter of the lesion. When electrocautery is used, inclusion of a rim of normal
mucosa is not strictly necessary, but is probably safe when submucosal fluid has been
injected and likely helps to ensure complete excision.
Large serrated lesions (most likely to be SSA/P) may actually be easier to snare than large
adenomas. This is because an SSA/P is generally less attached to the underlying submucosa
and can be drawn into the snare more easily. Submucosal injection of these lesions
sometimes makes resection more rather than less difficult by preventing the mucosal
wrinkling that facilitates snaring. There is no evidence that resection of large serrated lesions
is associated with an increased risk of complications despite their flat profile and proximal
location, and there may be a reduced incidence of post-polypectomy bleeding (71).
Piecemeal resection and application of argon plasma coagulation to destroy residual tissue
that cannot be snared are appropriate techniques, but of course, the endoscopic approach to
large serrated lesions will depend on lesion size, shape and location, as well as patient age
and comorbidities, and the experience and judgment of the endoscopist. When piecemeal
technique is used for large serrated lesions, another colonoscopy at 3 to 6 months is
recommended to check for completeness of excision. In challenging cases, referral to a more
experienced therapeutic colonoscopist should be considered.
Surgical resection of colon containing a serrated lesion is rarely necessary (71), but is
appropriate when a serrated lesion cannot be endoscopically excised. Surgical resection may
also be indicated when there are numerous large serrated lesions in the proximal colon.
Serrated polyposis syndrome
Serrated polyposis syndrome (SPS) (formerly hyperplastic polyposis syndrome) is
characterized by multiple serrated (typically SSA/Ps and/or HPs) colorectal polyps. Recently
updated WHO criteria define the syndrome by any one of the following conditions: (1) at
least five serrated polyps proximal to the sigmoid colon with two or more of these being >
10 mm; (2) any number of serrated polyps proximal to the sigmoid colon in an individual
who has a first-degree relative with SPS or (3) > 20 serrated polyps of any size, distributed
throughout the colon (125). However, this definition is arbitrary and cannot be validated
without a genotype, and no definitive gene mutation has yet been identified to correlate with
the phenotype.
There is substantial phenotypic diversity (125) and it is possible that several different but
related conditions may be part of SPS. SPS has near equal gender distribution (126–128),
with median age at diagnosis of 44 to 62 years, and range 10–90 years (126–128). Serrated
lesions in SPS are sessile polyps or flat lesions. Typically, most are < 1 cm in size, and
polyps > 1 cm are more often located in the proximal colon. Patients often have one or more
synchronous adenomas (126–128).
SPS demonstrates hallmarks of a genetic disease, including multiple lesions, younger age of
onset of lesions, family history of neoplasia, as well as restricted ethnicity in some studies
(129, 130), but most cases are sporadic. The polyposis is an indication of a “methylator
milieu” existing in the mucosa (131) and acquired either by inheritance or by exposure to as
yet unknown environmental agents.
The exact risk of CRC in SPS is unknown. Case series have reported up to 25% to 50% rates
of synchronous cancer at diagnosis (126–128, 132–138). A retrospective study found a
cumulative risk of CRC of 7% at 5 years in patients under surveillance (126). These
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estimates are subject to ascertainment bias, however, and the risk estimates are likely to be
inflated.
Surgery is generally indicated in SPS when CRC is diagnosed or when the size and/or
number of polyps makes endoscopic control not feasible. Surgery for patients with SPS
should include resection of any segment with cancer and at least those segments with large
polyps. Extended right hemicolectomy and subtotal colectomy are the most common
operations. Annual endoscopic surveillance of any residual colon and rectum is appropriate.
When long-term endoscopic management is attempted, annual colonoscopy should be
performed with intent to clear the proximal colon of all serrated lesions, or all serrated
lesions ≥ 5 mm in size if there are numerous diminutive lesions. The surveillance interval
and/or the management strategy can be altered if subsequent examinations reveal
progressive control or loss of control of the polyp burden.
Nearly half of SPS patients have a family history of CRC (128, 132), and one study reported
an elevated relative risk of CRC in first-degree relatives of patients with SPS of 5.4 (139). It
is recommended that screening colonoscopy be performed in first degree relatives aged ≥ 40
years, or beginning at an age 10 years younger than the age at diagnosis of the youngest
affected relative. Colonoscopy is recommended at 5 year intervals, or more frequently if
polyps are found.
Post-polypectomy surveillance of patients with serrated lesions
Post-polypectomy surveillance guidelines in the United States and Great Britain make
recommendations for patients with adenomas based on observational studies that link
baseline colonoscopy adenoma findings to the risk of an advanced adenoma at follow-up
(140, 141). There are few such data available for serrated lesions (81, 93, 99, 142), but the
strong association of serrated lesions with CIMP-high CRCs has led to calls for specific
post-polypectomy surveillance guidelines for patients with SSA/Ps. Several authors have
already made suggestions in this area (13, 17, 143–145). Recommendations for surveillance
are made here, but considering the paucity of post-polypectomy observational studies
addressing follow-up of serrated lesions, the recommendations reflect consensus expert
opinion. The recommendations are based on the principles presented in Figure 7, and the
collective approaches to serrated lesions of the panel members.
Major limitations of colonoscopy as a tool for preventing CRC include variable lesion
detection rates (146–150) and variability in efficacy of polypectomy (151). When the rate of
missed or persistent lesions varies significantly between endoscopists, it is difficult to make
surveillance guidelines that protect all patients. While this applies to adenomas as much as
to serrated lesions, cancers developing after colonoscopy are more likely to be right-sided,
MSI-high and CIMP-high, suggesting that missed serrated lesions may be a major reason for
the relative failure of colonoscopy to protect against right-sided colon cancers (152, 153).
Thus, the first concern of colonoscopists should be effective polyp detection and resection.
Because there are data describing standards for adenoma detection rate (ADR), and because
ADR correlates with serrated lesion detection in some studies (73, 119), colonoscopists
should know their ADR. If this is substandard (< 25% in average risk men over 50 years
having screening colonoscopy, < 15% for average risk women over 50 years) (121),
technique and or lesion recognition skills should be improved to bring the ADR into
acceptable range. No recommendation for a detection threshold of serrated lesions is made
here, but this issue is being actively studied. Available data indicate that miss rates and
variability in detection are greater for serrated lesions than for adenomas (73, 119).
Figure 7 presents the conceptual framework that underlies the risk stratification scheme
presented in Table 5. Much of this framework and its basis in the literature in discussed
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elsewhere in this paper. As noted above, the specific recommendations for interval follow-
up in Table 5 reflect consensus expert opinion rather than a substantial evidence base. As
post-polypectomy surveillance studies of serrated lesions become more available, evidence
based guidelines will be developed that will supersede such recommendations.
Accurate characterization of the number, size and location of lesions is dependent on the
endoscopist. Accurate characterization of histology is dependent on the pathologist. This
paper emphasizes the importance of effective detection and resection and also provides
pathologic criteria for the distinction between HP and SSA/P. Endoscopists and pathologists
should share this information and work cooperatively to improve care in their institution, but
clinicians should consider use of the SSA/P recommendation when proximal serrated lesions
> 1 cm in size are interpreted as HPs, as there is likely substantial variation between
pathologists in this regard. Endoscopy findings may be critical for interpretation of
histological findings and should be available to pathologists.
Given the paucity of observational studies after endoscopic resection of serrated lesions (81,
93, 99, 142), we sought other evidence to guide surveillance recommendations. We
identified several rationales for establishing relatively aggressive surveillance
recommendations (Table 5) following resection of serrated lesions pending availability of
additional observational studies. First, interval cancers (cancers occurring after colonoscopy)
are more likely to be right-sided, MSI-high and CIMP-high (152, 153). Given that
colonoscopy is less effective in preventing proximal than distal cancers (146, 147, 154, 155),
these data suggest that serrated lesions (and failure to detect serrated lesions) are an
important contributor to failure of colonoscopy to prevent colorectal cancer. Second, initial
studies have found that variability in detection of serrated lesions in the proximal colon is
greater (73, 119) than has been reported for adenomas (149, 150), supporting a rationale for
relatively close intervals to compensate for increased missing of serrated lesions. Third,
there are insufficient data on the effectiveness of endoscopic resection of serrated lesions.
However, the very flat shape of many SSA/Ps, combined with the indiscrete borders of these
lesions, raises concerns that incomplete resection of serrated lesions may be an important
clinical problem. These factors combine to create a tendency toward aggressive
recommendations after resection of serrated lesions. However, aggressive post-polypectomy
surveillance is acknowledged as a poor replacement for endoscopists who are well trained in
lesion recognition, examine the colon carefully, and resect pre-cancerous lesions completely.
Recommendations for post-polypectomy surveillance of patients with serrated lesions are
subject to modification based on physician judgment. If multiple types of serrated lesions
are present, the shortest recommended interval should be considered. Subsequent
colonoscopies that identify no lesions or serrated lesions that are fewer in number, smaller,
etc., can be followed by expansion of the interval. When synchronous serrated lesions and
conventional adenomas are present, opting for the shorter interval that would be appropriate
based on either type of lesion is acceptable or further shortening the interval based on
number of lesions of both types may be appropriate.
Summary
Serrated lesions should be classified as hyperplastic polyp, sessile serrated adenoma/polyp
(SSA/P) with or without cytological dysplasia, or traditional serrated adenoma (TSA). SSA/
P is located primarily in the proximal colon, and is an important precursor of colorectal
cancers. Cancers arising through the serrated pathway are typically CIMP-high, demonstrate
BRAF mutations, and may demonstrate MSI.
It has been recently proposed that the colorectum biologically represents a continuum, rather
than a two-sided tube with a sharp border at splenic flexure (47, 156). Evidence suggests
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that cecum may be a separate place from the other colorectal subsites, with a high frequency
of KRAS mutations in cecal cancers (47). Future research on serrated and other precursor
lesions needs more collaboration and adequate sample sizes to address biological, microbial,
and microenvironmental heterogeneity in detailed colorectal subsites.
SSA/Ps are flat or sessile with a distinct endoscopic appearance that is often quite subtle.
Effective colonoscopy requires understanding of the typical appearance of serrated lesions,
followed by accurate identification of these lesions. All serrated lesions proximal to the
sigmoid and rectosigmoid lesions > 5mm in size should be fully resected.
Recommendations for colonoscopy surveillance intervals must currently be based on
features of serrated lesions that are associated with advanced neoplasia including
synchronous and metachronous colorectal cancer. These features include proximal colon
location of serrated lesions, increasing number and larger size of serrated lesions, and SSA/P
or TSA histology.
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Photomicrographs of hyperplastic polyps. (a) Microvesicular hyperplastic polyp (MVHP).
The crypts and surface epithelium show a luminal serrated or saw-toothed contour more
prominent in the upper levels of the crypts than at the base. The epithelial layer is composed
of cells with goblet cell differentiation and others with microvesicular cytoplasmic mucin.
(b) Goblet cell hyperplastic polyp. In contrast to MVHP, this polyp shows a much less
pronounced serrated or saw-toothed luminal epithelial growth pattern and shows a
preponderance of goblet cells and an absence of cells with microvesicular mucin. The crypts
are straight, linear, and without architectural distortion. (c) Mucin poor hyperplastic polyp.
The overall configuration of this polyp is similar to the microvesicular hyperplastic polyp
but the cells are mucin depleted. The nuclei also are more hyperchromatic than the MVHP.
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Photomicrograph of sessile serrated adenoma/polyps. (a) A sessile serrated adenoma/polyp
showing a hyperserrated luminal epithelial growth pattern more pronounced that in
microvesicular hyperplastic polyps. In addition, the crypts show luminal dilation towards the
bases of the crypts, some crypts show horizontal growth along the long axis of the
muscularis mucosa (arrow). Goblet cells are present at all levels of the crypts, some of
which are dystrophic. Mitotic figures are easily recognized, and located predominantly in
the basal aspects of the crypts. (b) Sessile serrated adenoma/polyp with cytological
dysplasia. The portion of the polyp without cytological dysplasia on the left shows cells with
uniform nuclei without pseudostratification. The cytologically dysplastic portion on the right
(arrows) show hyperchromatic pseudostratified nuclei with numerous mitoses.
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Traditional serrated adenoma. This polyp is composed of villiform projections of
hypereosinophilic cells with small oval-shaped nuclei oriented basally along the basement
membrane. The cells are growing in a hyperserrated luminal contour. Multiple ectopic
crypts are present. These are composed of crypts oriented perpendicular to the long axis of
the villi. Overall, goblet cells are decreased in number.
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A schematic representation of the putative development of CIMP-high CRCs with
microsatellite instability through a serrated pathway via methylation of the MLH1 gene.
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Both sessile serrated adenoma/polyps and hyperplastic polyps in the proximal colon may
demonstrate a “mucus cap,” which may be yellow, green or rust-colored in white light (a)
and red in narrow-band imaging (b).
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Typical serrated lesions in the proximal colon. a–d. A sessile serrated adenoma/polyp in the
cecum. Note the adherent mucus in white light (a) and with narrow-band imaging (b). After
removal of the cap by washing the characteristics surface features are seen in white light (c)
and narrow-band imaging (d), including indistinct edges, color similar to the surrounding
normal mucosa, and a paucity of blood vessels. e–h. A flat sessile serrated adenoma/polyp in
the transverse colon, with the mucus cap in white light (e) and narrow-band imaging (f) and
with the cap washed off in white light (g) and blue light (h). Note the subtlety of the lesion
after the cap is washed off.
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The risk of developing colorectal cancers through the serrated pathway parallels the number,
size, type, and anatomic distribution of the serrated polyps.
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Table 1
Pathologic classification of serrated colorectal polyps recommended by the World Health Organization
• Hyperplastic polyp
• Sessile serrated adenoma/polyp*
– With or without cytological dysplasia
• Traditional serrated adenoma
The terms
*
”Sessile serrated adenoma” and “sessile serrated polyp” are considered synonymous
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Table 2
Key conclusions and recommendations of the consensus group*
Pathology
1 Serrated lesions of the colorectum should be classified histologically as hyperplastic polyp (HP), sessile serrated adenoma/polyp
(SSA/P) with or without cytologic dysplasia, or traditional serrated adenoma (TSA). Exceptions and subcategories are discussed in
the text. Clinicians and pathologists within institutions should work collaboratively to achieve a common usage and understanding
of terminology of serrated lesions.
2 SSA/P and TSA are pre-cancerous lesions. SSA/P is the principal precursor of hypermethylated colorectal cancers (cancers with
the CpG Island Methylator Phenotype – CIMP). This pathway occurs primarily in the proximal colon.
3 SSA/P is distinguished from HP pathologically by findings of crypt distortion, particularly in the crypt base, in SSA/P. We
recommend that a single unequivocal architecturally distorted, dilated, and/or horizontally branched crypt, particularly if it is
associated with inverted maturation, is sufficient for a diagnosis of SSA/P. Most large serrated lesions in the proximal colon are
SSA/Ps.
4 SSA/P with cytological dysplasia is a more advanced lesion in the progression to cancer compared to SSA/P without cytological
dysplasia.
Endoscopy
5 SSA/P and hyperplastic polyps in the proximal colon have a distinct endoscopic appearance, which includes a “mucus cap”, color
usually similar to normal mucosa, and indistinct edges. All colonoscopists should be able to recognize serrated lesions.
6 Detection of proximal colon serrated lesions by individual endoscopists is highly correlated with adenoma detection. Pending
development of specific detection targets for proximal colon serrated lesions, endoscopists should measure their adenoma
detection rates as a check on adequate detection of serrated lesions.
7 All serrated lesions proximal to the sigmoid colon should be fully resected during colonoscopy. All serrated lesions in the
rectosigmoid colon > 5 mm in size should be fully resected.
Surveillance
8 Serrated polyposis is defined by the World Health Organization (see text for details). Patients with serrated polyposis require close
endoscopic follow-up with control of polyp burden by endoscopy or by surgical resection if the number, size or location of
serrated polyps precludes endoscopic resection or if a cancer is diagnosed.
9 First degree relatives of patients with SPS should undergo colonoscopy at age 40 or 10 years before the age at diagnosis of SPS.
Colonoscopy should be at 5 year intervals or more often if polyps are found.
10 There are few longitudinal observational studies after removal of serrated lesions on which recommendations for post-
polypectomy surveillance can be based. Recommendations are mostly based on features of serrated lesions for which there is
evidence of an association with increased risk of cancer or advanced neoplasms, including: proximal colon location, large size,
increasing number, and histologic features including SSA/P histology (see text and Table 5, Figure 7 for details).
*
Clinical recommendations made here are considered strong by the panel, but are supported by low quality or very low quality evidence, and are
likely to change when higher quality evidence becomes available.
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Table 5
Consensus opinion surveillance intervals after endoscopic resection of serrated lesions+
Histology Size Number Location Interval in years
HP < 10 mm any number* rectosigmoid 10***
HP ≤ 5 mm ≤ 3 proximal to sigmoid 10
HP any ≥ 4 proximal to sigmoid 5
HP > 5 mm ≥ 1 proximal to sigmoid 5
SSA/P or TSA < 10 mm < 3 any 5
SSA/P or TSA ≥ 10 mm 1 any 3
SSA/P or TSA < 10 mm ≥ 3 any 3
SSA/P ≥ 10 mm ≥ 2 any 1–3***
SSA/P w/dysplasia any any 1–3****
+
 The interval recommendations presented here represent consensus opinion based on low quality or very low quality evidence. They are likely to
change as higher quality evidence becomes available, and alternatives may be equally reasonable.
*
Patients with > 20 HPs in the rectosigmoid meet the World Health Organization definition of serrated polyposis if there are additional serrated
lesions proximal to the sigmoid.
**
Some panel members follow a policy of 5 years if there are multiple HPs 6–9mm in size in the rectosigmoid.
***
Patients with 2 or more serrated polyps ≥ 10 mm in the proximal colon meet the World Health Organization criteria for serrated polyposis if 3
additional serrated lesions of any size are proximal to the sigmoid are identified.
****
SSA/P with cytological dysplasia is a more advanced lesion than SSA/P. Depending on the size of the lesion, the confidence in complete
endoscopic resection, and other associated lesions, intervals shorter than 3 years may be appropriate.
+
 Grade: see definitions of grade recommendations in Table 3.
Note 1: Patients with both significant serrated polyp findings and concurrent adenomas may be at a more advanced stage in the progression toward
cancer. Closer follow up may be indicated in some cases based on clinical judgment.
Note 2: In general, these recommendations for surveillance are for the first follow up. For findings with short follow up recommendations, a longer
subsequent follow up interval may be appropriately applied when a follow up exam shows improvement in findings, i.e. reductions in the number,
size, and/or histologic severity of lesions.
Note 3: Because of interobserver variation in the pathologic differentiation of HP from SSA/P, proximal colon serrated lesions > 10 mm in size that
are designated HP may be considered to be SSA/P by clinicians.
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